Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer

Benzer Materyaller

• Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
  Yazar:: Subudhi, Sumit K., ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
  Yazar:: Gao, Jianjun, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
  Yazar:: Bilen, Mehmet Asim, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
  Yazar:: Sinha, Meenal, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
  Yazar:: Gao, Jianjun, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)